Use of the drug eluting stents with rapamicin in patients with anatomical or clinical patterns favouring restenosis: results of a 6-months follow-up on the first 100 patients. Intenational Angiology. 2004. 23(suppl.1)

PEAK PARTICLE SIZE AND THE EXTENSION OF CORONARY ATHEROSCLEROSIS IN 71 PATIENTS THAT UNDERWENT AN ANGIOGRAPHIC EXAM

Family hystory, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: a one year follow-up study

BACKGROUND AND AIM: In this study we addressed some open questions in patients with coronary artery disease (CAD). First, we analysed which of the traditional risk factors was associated with the spreading of coronary stenosis and second, we aimed to identify if any variable was predictive of post-percutaneous transluminal coronary angioplasty (PTCA) clinical events. METHODS AND RESULTS: We collected a consecutive series of patients with CAD (n=301) and in the subgroup of patients undergoing PTCA (n=135) we performed a prospective one-year follow-up study recording cardiovascular morbidity and total mortality. According to the extension of coronary atherosclerosis, we found a significant re…

EFFETTI “BEYOND CHOLESTEROL” DELLE STATINE

Excimer laser technology in percutaneous coronary interventions: Cardiovascular laser society's position paper

Excimer Laser Coronary Atherectomy (ELCA) is a well-established therapy that emerged for the treatment of peripheral vascular atherosclerosis in the late 1980s, at a time when catheters and materials were rudimentary and associated with the most serious complications. Refinements in catheter technology and the introduction of improved laser techniques have led to their effective use for the treatment of a wide spectrum of complex coronary lesions, such as thrombotic lesions, severe calcific lesions, non-crossable or non-expandable lesions, chronic occlusions, and stent under-expansion. The gradual introduction of high-energy strategies combined with the contrast infusion technique has enabl…

Effects “beyond-cholesterol” by statins: a 3-months therapy with simvastatin reduces the atherogenic lipoproteins in patients with premature coronary artery disease and in absence of the traditional cardiovascular risk factors.

Diabetes, family history and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: a one year follow-up study. Intenational Angiology. 2004. 23(suppl.1)

Diabetes, family hystory and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: a one year follow-up study